Know exactly which claims your evidence can defend.

Probara validates every marketed claim against PubMed clinical evidence, checks dose and population match per FTC 2022 standards, flags Amazon enforcement risk, and hands you the strongest defensible version of each claim.

Run your product free →

Flagged claim. Defensible reframe. Methodology named.

For every claim your evidence can't fully support, Probara produces a reframe: what you can defensibly say, grounded in dose-matched, population-matched study evidence, with the FTC 2022 standard cited by name. Not editorial opinion. A traceable standard.

Every rewrite traces to a named standard, not editorial judgment.

Flagged "Clinically proven to eliminate stress and anxiety."
Defensible "Formulated with ashwagandha, studied in stressed adults for its role in supporting a normal stress response." (GRADE B · 25 studies · FTC 2022 standard)

Illustrative example. Advisory guidance only. Confirm final wording with your regulatory or legal review.


Real dossier excerpt. Real ashwagandha evidence.

This is a live excerpt from a Probara dossier on ashwagandha 600 mg (KSM-66). Every GRADE verdict, study count, dose-match figure, and PMID is drawn directly from the evidence pipeline, not illustrative. Your product's claims run through the same review.

  • Amazon §6.10.4 content check
  • GRADE B (moderate certainty)
  • FTC 2022 substantiation match
  • DSHEA structure/function framing

Brand Evidence Dossier

Ashwagandha (KSM-66 600 mg) · Probara review

Plain-language verdicts for every marketed claim, each graded against the weight of the evidence.

Moderate confidence GRADE B Structure/Function claim · FTC compliant

Anxiety reduction

25 independent studies · population: stressed adults · product-specific

25 studies Dose match: 6/13 studies
36017529 39348746 42105298 41906501 37878284
PMID 36017529 Meta-analysis, 12 RCTs (N = 1,002). Anxiety SMD −1.55 (95% CI: −2.37 to −0.74; P = .005; I² = 93.8%). Dose-response peak at 300–600 mg/day. Limitation: very high heterogeneity limits interpretability.
PMID 39348746 Meta-analysis, 9 RCTs (N = 558). HAM-A MD −2.19 (95% CI: −3.83 to −0.55). Cortisol MD −2.58 (95% CI: −4.99 to −0.16).
PMID 34559859 Meta-analysis, 5 RCTs (N = 400). Overall sleep SMD −0.59 (95% CI: −0.75 to −0.42; I² = 62%). Effect more prominent: insomnia subgroup, ≥600 mg/day, duration ≥8 weeks.
PMID 32818573 Multicenter RCT, n = 80 (healthy + insomnia), × 8 weeks. Significant improvement in Sleep Onset Latency (P = .013), Sleep Efficiency (P < .0001), TST, WASO, PSQI, HAM-A.
PMID 40746175 Meta-analysis, 7 RCTs (n = 488). Cortisol: −1.16 μg/dL (95% CI: −1.64 to −0.69; P < .001; I² = 50.9%). Critical null finding: No significant PSS effect (SMD −0.355; P = 0.40).
PMID 27055824 RCT, n = 52, KSM-66 300 mg × 2 daily (600 mg/day) × 8 weeks. Serum cortisol significantly reduced vs. placebo. PSS also significantly improved. Only study explicitly using KSM-66 at the labelled 600 mg dose.

Clinical study dose range

120–1,000 mg/day across reviewed RCTs and meta-analyses. Most commonly studied range: 300–600 mg/day. Duration: 30–112 days; majority of studies 8–12 weeks.

Common adverse effects (clinical trials)

Most commonly reported in RCTs: somnolence/drowsiness, epigastric discomfort, loose stools/diarrhea, nausea, mild headache, giddiness. Mild and transient in the majority of trials. No serious adverse events (SAEs) reported in most included RCTs.

Explicit list of open evidence gaps. Nothing on the label is overstated beyond what the evidence supports.

  1. Long-term safety: No RCT in the evidence pool exceeded 16 weeks. Safety of continuous use beyond 3–4 months has not been established in controlled settings.
  2. KSM-66-specific dose-response data: The evidence pool contains only one study (PMID 27055824) explicitly using KSM-66 at the labelled 600 mg dose.

Research tool disclosure. This dossier is produced by an evidence synthesis research tool. Based on published biomedical literature, provided for educational and research purposes only. Not medical advice, diagnosis, or treatment recommendation. Does not constitute Competent and Reliable Scientific Evidence (CRSE) as defined by the FTC. That determination requires review by qualified regulatory professionals.

See pricing →

Five validations every claim runs through.

Every dossier applies the same deterministic gates, in the same order, against PubMed clinical evidence. No editorial shortcuts.

PubMed/MEDLINE-only clinical evidence core. No grey literature, no press releases.
GRADE certainty gates claim strength. Low or very-low evidence cannot use strong language.
Amazon enforcement-risk score per claim. Flags §6.10.4 content policy exposure before listing review.
  • Per-claim dose-match validation: clinical study doses compared to your labelled dose (MATCH / PARTIAL / MISMATCH), applied against the FTC 2022 standard deterministically.
  • Per-claim population-match validation: study population compared to your marketed-to population, per the FTC 2022 standard.
  • GRADE certainty graded per outcome: study quality gates claim language. Weak evidence enforces conditional phrasing.
  • PubMed/MEDLINE-only clinical evidence core: every supporting study traceable to a real PMID.
  • Amazon enforcement-risk score per claim: §6.10.4 content policy applied per claim before your listing is reviewed.

Compliance consultants bill by the hour to surface these gaps. Probara delivers the same structured analysis before they start the clock.


Common questions

I've never heard of Probara. How do I know this is real?

Skip the brand story and look at the output instead. The sample dossier above shows an actual ashwagandha evidence report with real PubMed citations and quality-gate verdicts. Run one of your own products free and you'll see a real finding on your specific ingredients in about 30 seconds. If it doesn't tell you something useful about your own product, you've lost nothing.

The free check seems simple. What is the actual product?

The free check is designed to be simple. The product behind it is not. For each ingredient, Probara pulls peer-reviewed studies from PubMed, cross-references the NIH supplement database, applies a battery of deterministic quality gates per claim, and produces a submission-ready evidence package. That is what a spreadsheet cannot do.

Is this just a generic compliance checklist?

No. The evaluation is specific to your product. A turmeric supplement on Amazon produces a different result than a vitamin D on Shopify because the requirements are actually different. Ingredient-conditional items like pesticide screening fire for botanicals and pass automatically for non-herbals. Channel-conditional items like TIC selection apply only to Amazon sellers. The logic changes because your inputs change.

What if a claim is still flagged after your review?

That is exactly what the guarantee covers. We revise free against our published standard until your claim set meets it. If it still fails your own regulatory counsel's review, you get a full refund. We do not promise that a claim will never be questioned; no one can. We do stand behind the standard we applied. The goal is a claim set you can defend, not one that merely feels safer.

We already work with a regulatory consultant.

Probara is not a replacement for your consultant. It is a better starting point for them. Right now they likely spend the first hour of every engagement identifying where the gaps are. Probara delivers a structured gap report before they start the clock. Your consultant's judgment is what resolves the gaps. Probara surfaces them faster.

Our manufacturer handles compliance for us.

Your manufacturer is responsible for their facility's GMP certificate and their internal quality processes. Amazon holds the brand owner responsible for the COA documentation and the labeling and testing records tied to your specific SKU. That split is where most brands get caught. A compliance notice goes to your seller account, not your manufacturer's address.

Does it actually check my product, or is the output generic?

The evaluation is tied to what you put in. If you have ashwagandha in your formula, pesticide screening fires. If you hold NSF or USP certification, fast-track eligibility changes. If you sell only on Shopify, the Amazon-specific TIC selection item passes automatically.

We have 50 or more SKUs. Can this handle that volume?

Each product runs as an independent check with no setup or configuration per SKU. At 50 products you are looking at under 30 minutes to have a compliance snapshot across your full catalog. Most brands find a small number of SKUs doing most of the work. This is how you find out which ones.

Why is this paid and not free?

The free check delivers one real finding as a proof of value. A full dossier is a submission-ready evidence package: primary literature pulled, GRADE-graded, mapped to FTC substantiation standards, with reframe copy included. That work has real cost. The price reflects what a compliance consultant bills for a fraction of it.

What is founding-client pricing?

Founding-client pricing is a discount applied at checkout for the first cohort. The list prices you see are the post-cohort rates. Founding clients lock in the lower rate and get direct access for feedback during the initial build period. We apply the code at checkout. You do not need to negotiate or ask.

Can I start with just one product?

Yes. The Single Dossier tier covers one SKU, full dossier, at $1,499. If you later want to expand to five or more SKUs, the full $1,499 credits forward toward the Starter tier. You never pay twice for the same ground.

Ready to see full details?

See pricing →

Free compliance check

See one real finding on your product, free.

See one real, defensible finding on your own product, free. No call required.

We pull the ingredients and label for you. No typing.

or

A clear phone photo works.
Where we send your free finding. No call required.
Prefer to type it in manually?

Our guarantee: we revise free against our published standard until your claim set meets it. If it fails your own regulatory counsel's review, you get a full refund.

Advisory only. Not legal or regulatory advice. You remain responsible for final compliance review.